AI Summary
We reviewed 11 live results for bevacizumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
Mvasi (bevacizumab)
Source: Amgen
Description
Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility.
Best for
metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care
View Details
Rating
Bevacizumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Best for
solid tumor treatment, cancer therapy and oncology clinics
Tags
View Details
Rating
Mvasi (bevacizumab)
Source: Amgen
Description
Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment.
Best for
Oncology patients, Metastatic cancer treatment and Subsidized medical care
View Details
Rating
| Compare | Mvasi (bevacizumab) | Bevacizumab Biosimilar | Mvasi (bevacizumab) |
|---|---|---|---|
| Source | Amgen | Biocon Biologics Philippines Inc. | Amgen |
| Description | Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility. | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. | Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment. |
| Best for | metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care | solid tumor treatment, cancer therapy and oncology clinics | Oncology patients, Metastatic cancer treatment and Subsidized medical care |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Mvasi (bevacizumab) from Amgen."
I picked this because Mvasi is a clinically validated biosimilar registered with the NPRA in Malaysia, offering a recognized treatment path for multiple oncological conditions including colorectal and lung cancers.
Share this search
Related Finds